Genprex, Inc. (GNPX) Form 8-K — Jun 12, 2026
Genprex, Inc. (GNPX) received a letter from Nasdaq indicating that its common stock will be delisted from The Nasdaq Capital Market unless the company timely requests a hearing before a Nasdaq Hearings Panel. The delisting determination stems from the company’s failure to maintain the required $1.00 minimum bid price for 30 consecutive business days. Nasdaq determined that Genprex is ineligible for the standard 180-day compliance period because the company effected a reverse stock split on October 21, 2025, within the prior one-year period.
Key figures
- Non compliance period
- 30 consecutive business days
- Prior reverse split date
- October 21, 2025
- Minimum bid price requirement
- $1.00
Price after filing
Close on the filing date to close N calendar days later (from $0.65). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.